Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Predictive Oncology Inc. Announces Completion of $3.5 Million Private Placement
MINNEAPOLIS , March 23, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
View HTML
Toggle Summary Predictive Oncology Inc. Announces $3.5 Million Private Placement
MINNEAPOLIS , March 16, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
View HTML
Toggle Summary Predictive Oncology Launches New AI Platform for Vaccine and Drug Development Targeting Coronaviruses and Acute Respiratory Syndromes (COVID-19, MERS, and SARS)
With More Viral Outbreaks Expected, Predictive Oncology Expands AI Platforms to Aid in Vaccine and Drug Development MINNEAPOLIS , March 12, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“POAI” or “the Company”), a knowledge-driven company focused on applying artificial
View HTML
Toggle Summary Predictive Oncology Provides Acquisition Update, Stresses Importance of AI in New Anti-Cancers, Anti-Virals and Vaccines
POAI proposed acquisition of Carnegie Mellon University spin-out Quantitative Medicine further positions the company to aid in efforts to accelerate the discovery of new anti-cancers, anti-virals, antibiotics and vaccines MINNEAPOLIS , March 02, 2020 (GLOBE NEWSWIRE) -- Amid mounting concern over
View HTML
Toggle Summary Predictive Oncology Inc. Appoints Dan Handley, M.S., Ph.D. to Board of Directors
MINNEAPOLIS , Feb. 21, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
View HTML
Toggle Summary Predictive Oncology Launches Innovative Specialty Media for Growing Ovarian Tumors in the Lab
New Formulations Will Speed Discovery of Biomarkers and Precision Therapies MINNEAPOLIS , Feb. 05, 2020 (GLOBE NEWSWIRE) -- TumorGenesis, Inc. a subsidiary of Predictive Oncology, Inc. (NASDAQ: POAI) has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor
View HTML
Toggle Summary Predictive Oncology Inc. Signs Letter of Intent to Acquire Quantitative Medicine (qtmed.com) and an AI Engine™ (CoRE™) that Facilitates Accelerated Drug Discovery and Development
AI platform was developed at the Ray and Stephanie Lane Center for Computational Biology, which became the Computational Biology Department at Carnegie Mellon University and was successfully tested by several pharma companies MINNEAPOLIS , Jan. 24, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc.
View HTML
Toggle Summary Predictive Oncology Inc. Appoints Pam Prior to Board of Directors
MINNEAPOLIS , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
View HTML
Toggle Summary Predictive Oncology Inc. Announces Extension Of Promissory Note Due December 31, 2019
MINNEAPOLIS , Dec. 17, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
View HTML
Toggle Summary Predictive Oncology Provides Updates on Commercialization of Its Cancer Quest 2020 Initiative
MINNEAPOLIS , Dec. 09, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
View HTML